2X1:ETR
Abivax SA
€77.10
arrow_upward
+0.26%(+0.20) 1D
Okt 14, 9:04:40 AM GMT+2 · EUR
search
Lahat ng simbolo
| Simbolo | Presyo | Palitan | % ng Pagbabago |
|---|
insights_autoBumubuo ng mga nangungunang insight para sa 2X1...
Buksan
€77.10
Mataas
€77.10
Mababa
€77.10
Mkt. cap
6.78B
Avg. na dami
1.79K
Dami
5.00
Mataas nang 52-wk
€137.40
Mababa nang 52-wk
€60.85
EPS
-€5.20
Bilang ng mga empleyado
98
Buksan
€77.10
Mataas
€77.10
Mababa
€77.10
Mkt. cap
6.78B
Avg. na dami
1.79K
Dami
5.00
Mataas nang 52-wk
€137.40
Mababa nang 52-wk
€60.85
EPS
-€5.20
Bilang ng mga empleyado
98
Mga balita at kwento
Mula sa mga source sa web at partner sa balita
Idéal Investisseur
·
19 oras ang nakalipas
Abivax stock breaks below its 77.10 € support level despite Goldman Sachs buying recommendation
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
Tungkol sa Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Mga Empleyado98
ItinatagDis 4, 2013
Headquarters-
Sektor-
Websiteabivax.com